Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: A08AX01

Acomplia(rimonabant)

Obesity

Marketing Authorisation Holder: sanofi-aventis

EMA Authorisation: 19/06/2006

INN: rimonabant

Indication

As an adjunct to diet and exercise for the treatment of obese patients (BMI 30 kg/m2), or overweight patients (BMI 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Acomplia — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.